Idiopathic Inflammatory Myositis Industry Assessment, 2020-2034: Breakthrough Therapies (Dazukibart and Efgartigimod) Propel Market Expansion Across the 7MM
December 11, 2024 07:01 ET
|
Research and Markets
Dublin, Dec. 11, 2024 (GLOBE NEWSWIRE) -- The "Idiopathic Inflammatory Myositis - Market Insights, Epidemiology, and Forecast to 2034" report has been added to ResearchAndMarkets.com's offering. ...
US Hematologists Express High Unmet Need in Treatments for Warm Autoimmune Hemolytic Anemia and Cold Agglutinin Disease
July 24, 2024 14:00 ET
|
Spherix Global Insights
EXTON, PA, July 24, 2024 (GLOBE NEWSWIRE) -- Autoimmune hemolytic anemia (AIHA) encompasses a group of rare disorders characterized by the destruction of red blood cells due to autoantibodies. Among...
Global Biosimilar Market Size to Reach USD 132.47 Billion in 2032 | Emergen Research
December 05, 2023 09:23 ET
|
Emergen Research
Vancouver, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Global Biosimilar Market Poised for Rapid Growth with 17.9% CAGR, Fueled by Rising Cancer Cases and Regulatory Approvals In 2032, the global biosimilar...
Rituximab Biosimilars Global Market Report 2022: Major Players Collaboration in Development Driving Sector Forward
August 09, 2022 05:28 ET
|
Research and Markets
Dublin, Aug. 09, 2022 (GLOBE NEWSWIRE) -- The "Rituximab Biosimilars Global Market Report 2022: By Application, By Distribution, By Route" report has been added to ResearchAndMarkets.com's offering....
Global Rituximab Biosimilars Market Opportunities and Strategies Report 2021-2030: Focus on Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Rheumatoid Arthritis
July 06, 2021 05:18 ET
|
Research and Markets
Dublin, July 06, 2021 (GLOBE NEWSWIRE) -- The "Rituximab Biosimilars Global Market Opportunities and Strategies to 2030: COVID 19 Growth and Change" report has been added to ResearchAndMarkets.com's...
China Rituximab Market Report 2021-2025: A Monoclonal Antibody to Target Cells that have the CD20 Marker on their Surface
May 13, 2021 05:53 ET
|
Research and Markets
Dublin, May 13, 2021 (GLOBE NEWSWIRE) -- The "Investigation Report on China's Rituximab Market 2021-2025" report has been added to ResearchAndMarkets.com's offering. According to this market...
Global Osteoporosis Disease Analysis Market Report 2020: Novartis has the Highest Number of Completed Clinical Trials for Osteoporosis with 120 Trials
February 01, 2021 06:38 ET
|
Research and Markets
Dublin, Feb. 01, 2021 (GLOBE NEWSWIRE) -- The "Disease Analysis: Osteoporosis" report has been added to ResearchAndMarkets.com's offering. Osteoporosis is the most common metabolic bone disease, and...
Global Rituximab Biosimilars Market Report 2020-2030: COVID-19 Impacts, Growth and Change
January 07, 2021 09:53 ET
|
Research and Markets
Dublin, Jan. 07, 2021 (GLOBE NEWSWIRE) -- The "Rituximab Biosimilars Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering. Rituximab...
Rituximab Biosimilar Insight report on 35+ companies and 35+ marketed and pipeline drugs | DelveInsight
October 29, 2020 18:00 ET
|
DelveInsight Business Research LLP
LA, USA, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Rituximab Biosimilar Insight report on 35+ companies and 35+ marketed and pipeline drugs by DelveInsight “Rituximab– Biosimilar Insight, 2020” by...
MMR Information Systems Pursues International Patent Applications on Anti-CD20 Antibodies
June 22, 2009 08:44 ET
|
MMR Information Systems, Inc.
LOS ANGELES, CA--(Marketwire - June 22, 2009) - MMR Information Systems, Inc. (OTCBB: MMRF) (the "Company"), which through its wholly-owned operating subsidiary,
MyMedicalRecords, Inc. ("MMR")...